Medical Compatibility and Cross-Species Clinical Reference
Internal Archive: Diegetic Lore
Purpose and Limits
This appendix supports initial emergency stabilization of baseline, unmodified adult Syliri and Vyrkani patients in mixed facilities. It is a routing aid, not a formulary, dosing guide, or substitute for specialist judgment.
Pediatric patients; patients receiving reproductive care or who are pregnant; and advanced-age, engineered, rare-lineage, or otherwise variant patients fall outside this baseline. Route them to the current specialist reference at once. If species or variant status is uncertain, treat the patient as outside the baseline until identity and physiology are confirmed.
All fluids, environmental settings, anesthetics, drugs, sterilants, implants, and toxicology measures must come from the current species-specific formulary. A generic product label is not evidence of compatibility.
I. Emergency Compatibility Matrix
| Decision point | Syliri baseline | Vyrkani baseline | Clinical rule |
|---|---|---|---|
| Oxygen carrier and visible blood | Iron-heme carrier within erythrocyte-equivalent cells; oxygenated blood is red. | Copper-based, hemocyanin-like carrier largely dissolved in plasma; oxygenated blood is blue to blue-green. | Confirm oxygenation instrumentally. Do not infer it from blood, skin, or scale color across species. |
| Blood transfusion | Compatible within validated standard Syliri matching protocols. | Compatible within validated Vyrkani carrier-protein matching constraints. | PROHIBITED: Never transfuse Syliri blood into a Vyrkani patient or Vyrkani blood into a Syliri patient. The incompatibility is fatal; this appendix does not assert a universal time course or single mechanism. |
| Crystalloid and volume replacement | Species-validated isotonic saline-equivalent formulations are compatible. | Species-validated isotonic saline-equivalent formulations are compatible. | Use the current species formulary. Do not substitute an unvalidated fluid because it is described as isotonic. |
| Plasma expansion | Metal-free synthetic expanders can be compatible; protein-rich substitutes require Syliri formulation. | Metal-free synthetic expanders can be compatible; protein-rich substitutes require Vyrkani formulation. | "Metal-free" is necessary where specified but is not sufficient. Confirm the complete formulation and species validation. |
| Atmospheric and thermal support | Optimized for a comparatively narrow, human-adjacent oxygen range; heat and cold tolerance are human-adjacent. | Baseline populations tolerate broader oxygen and temperature ranges. | Current standard imperial atmospheric baselines are safe for both. In care, use current species-specific targets; neither baseline is an operational guarantee for an injured individual. |
| Bleeding and wound response | Baseline clotting is rapid and human-adjacent. Bruising and wound presentation are usually familiar. | Baseline clot formation is slower and relies more heavily on pressure and scale closure. | Control bleeding under the current species trauma protocol. Do not assume a rate, endpoint, or hidden-wound severity from the baseline alone. |
| Visible injury assessment | Skin tone varies widely, but blood remains red and baseline bruising patterns are medically legible. | Scale color can obscure bruising; blood color differs; interscale and subscale injury may be hidden. | Expose and assess the actual injury. Use monitoring and imaging rather than color alone. |
| Thermal injury | Susceptibility is human-adjacent. | Greater baseline tolerance is observed; scale damage can complicate examination and treatment. | Use species-specific burn and exposure protocols. Do not delay treatment because the patient belongs to the more tolerant baseline. |
| Immediate pharmacology | Human-adjacent effects exist, but compatibility is not universal. Copper-reactive drugs are contraindicated outside controlled Syliri protocols. | Iron-reactive drugs may interfere with copper-transport proteins. Redox agents may interfere with oxygen-carrier function. | Verify every drug, carrier, and antidote in the current species formulary before administration. |
| Antioxidants and redox agents | Generally well tolerated; they may subtly alter skin undertone. | Must be screened for interference with hemocyanin-like oxygen binding. | Use the current species pharmacology formulary and monitor the named system. |
| Copper chelation | Copper chelation can be survivable under validated Syliri protocols and may disrupt dermal pigmentation. | RED ALERT: Copper chelators are life-threatening and prohibited by this baseline reference. | Do not improvise Vyrkani chelation. Treatment of Vyrkani copper poisoning remains an unresolved specialist matter in this appendix; escalate immediately and follow current toxicology direction. |
II. Procedure, Exposure, and Continuing-Care Matrix
| Domain | Syliri baseline | Vyrkani baseline | Required routing |
|---|---|---|---|
| Anesthesia and sedation | Human-adjacent anesthetic protocols are effective when validated for Syliri use. | Species-specific dosing and monitoring are required. | Use the current species anesthesia formulary. Do not derive dose from oxygen-carrier chemistry or anatomy alone. |
| Sterilants | Standard agents are safe when validated for Syliri use. | Copper-reactive disinfectants are contraindicated. | Confirm the agent and application in the current species procedure reference. |
| Implants and prosthetics | Metal implants are acceptable after standard Syliri biocompatibility screening. | Copper content and copper interaction require species-specific control to avoid metabolic overload. | Use the current species implant registry and specialist review. |
| Heavy-metal exposure | Copper exposure is moderately toxic; iron overload is dangerous. | Iron is generally tolerated; copper overload is acutely dangerous. | Route diagnosis and treatment through the current species toxicology reference. Do not infer a safe exposure threshold from this summary. |
| Oxidative exposure | Moderate vulnerability to oxidative stress is documented. | Extreme oxidation degrades hemocyanin-like carrier function. | Use current species-specific exposure and oxygenation guidance. |
| Radiation exposure | Dermal photoprotection mitigates ultraviolet injury independently of visible shade; mechanism and limits remain unsettled. Ionizing radiation remains harmful. | Scaled regions provide limited observed radiation attenuation. This is not whole-body shielding. | Treat radiation exposure under the species-specific protocol. Do not reduce protection or treatment because of pigment or scales. |
| Dietary metals | Iron is required; copper intake is regulated and limited. | Copper is required; iron is secondary. | Routine nutrition and metabolic correction require the current species nutrition formulary. |
| Cross-species diets | Sustained use of a Vyrkani-optimized diet creates copper-toxicity risk. | Sustained use of a Syliri-optimized diet creates copper-deficiency risk. | Do not use the other species' diet as continuing care without specialist review. |
III. Emergency Rules
- Confirm species, variant status, and the presence of an integrated cysuit before selecting products or settings.
- Stabilize through the current species protocol. When the proper reference is unavailable, obtain specialist direction and use the patient's verified cysuit clinical interface where present.
- Never perform a Syliri-Vyrkani blood transfusion. Use only verified, species-matched blood components under the applicable matching protocol.
- Do not infer oxygenation, perfusion, or injury severity from visible color alone.
- Do not treat "isotonic," "metal-free," "standard," or "human-adjacent" as proof that a fluid, drug, or device is compatible.
- Escalate a Vyrkani case involving copper chelation or copper poisoning immediately. This appendix supplies no rescue regimen.
IV. Cysuits and Partnered Care
The cysuit is active, integrated medical hardware. It monitors the wearer, may already be controlling hemorrhage or supporting organ function, and may carry a local clinical library. Coordinate through its clinical interface and with authorized clinical and cysuit practitioners. Do not assume that the visible surface can be moved, disabled, isolated, or treated as ordinary clothing without consequence.
The Syliri word cythralainn names the cysuit. It does not name the bond or the partnership.
When a Synthetic partner is present, biological intervention on the wearer is also clinical contact with the Synthetic through the shared interface. The two people nevertheless retain distinct authority over themselves.
| Situation | Governing rule |
|---|---|
| Intervention on the wearer's body | The wearer's consent governs. A Synthetic partner does not acquire authority over the wearer's body by sharing its sensory channel. If the wearer lacks capacity, follow the applicable emergency and capacity protocol. |
| A Synthetic partner is present | Inform and include the Synthetic as a separately affected person whenever the situation permits. Explain expected effects on shared perception and communication. Inclusion does not replace the wearer's consent. |
| Direct action on the Synthetic's substrate or interface | Obtain the Synthetic's separate consent. Any emergency exception must arise from the applicable personhood and clinical authority, not from treating the Synthetic as equipment. |
| Anesthesia, sedation, or altered consciousness | These interventions change what the Synthetic can perceive through the shared interface but do not, by themselves, interrupt the Synthetic's continuity. Assess separately for trauma or interface damage that may do so. |
| Cysuit intervention | Coordinate with the active clinical interface and authorized practitioners. Account for current life-support functions before changing, suppressing, or bypassing any cysuit system. |
| Death of the wearer | The partnered Synthetic withdraws to available compatible substrate before cysuit dissolution completes. Support transfer where possible, confirm continuity with the survivor, and provide practical and psychological care after the death. Matrix-01 is common but not required. |
V. Synthetic Patients Outside a Biological Body
The biological matrices above do not apply directly to a Synthetic residing in a robot, habitat, starship, or other computational substrate. Synthetics as a species have no biological transfusion requirement, organic metabolism, scale anatomy, or dietary-metal requirement. The Synthetic remains a patient and a person. Care may require substrate engineers alongside clinicians, with attention to energy, cooling, radiation, hardware integrity, continuity, cognition, and psychological well-being.
Mental-health care is one part of this broader practice rather than a substitute for substrate and continuity care.
Chapter 6 governs Synthetic embodiment and health. Chapters 7a and 7b govern cysuit operation, partnership, separation, death, and continuity.
Clinical Note
Syliri and Vyrkani can share environments and infrastructure while remaining clinically distinct. Similarity guides orientation; verified species identity, current references, and patient-specific evidence govern care.